Sana Biotechnology (NASDAQ:SANA) Rating Increased to Buy at TD Cowen

TD Cowen upgraded shares of Sana Biotechnology (NASDAQ:SANA) from a hold rating to a buy rating in a research note published on Wednesday, MarketBeat.com reports.

Several other equities analysts have also recently weighed in on SANA. HC Wainwright restated a “buy” rating and issued a $8.00 price objective on shares of Sana Biotechnology in a report on Wednesday, November 27th. JMP Securities downgraded Sana Biotechnology from an “outperform” rating to a “market perform” rating in a research note on Tuesday, November 5th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, Sana Biotechnology presently has a consensus rating of “Moderate Buy” and a consensus target price of $14.25.

Sana Biotechnology Stock Performance

NASDAQ SANA opened at $3.66 on Wednesday. Sana Biotechnology has a 52 week low of $1.52 and a 52 week high of $12.00. The stock’s 50 day moving average price is $2.40 and its two-hundred day moving average price is $4.06. The stock has a market capitalization of $817.16 million, a price-to-earnings ratio of -2.61 and a beta of 1.45.

Sana Biotechnology (NASDAQ:SANA) last announced its quarterly earnings data on Friday, November 8th. The company reported ($0.25) EPS for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.01. On average, equities research analysts forecast that Sana Biotechnology will post -1.16 EPS for the current year.

Insider Activity

In other Sana Biotechnology news, insider Fmr Llc sold 290,912 shares of the business’s stock in a transaction that occurred on Wednesday, January 8th. The stock was sold at an average price of $6.49, for a total transaction of $1,888,018.88. Following the transaction, the insider now owns 4,541,511 shares of the company’s stock, valued at $29,474,406.39. The trade was a 6.02 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 31.10% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Wilmington Savings Fund Society FSB bought a new stake in Sana Biotechnology in the 3rd quarter valued at $29,000. Stifel Financial Corp bought a new position in shares of Sana Biotechnology in the third quarter valued at about $43,000. EP Wealth Advisors LLC acquired a new stake in shares of Sana Biotechnology during the 3rd quarter worth about $45,000. Blue Trust Inc. boosted its holdings in shares of Sana Biotechnology by 1,246.6% during the 3rd quarter. Blue Trust Inc. now owns 13,129 shares of the company’s stock worth $55,000 after buying an additional 12,154 shares during the period. Finally, Cornercap Investment Counsel Inc. acquired a new position in Sana Biotechnology in the 3rd quarter valued at about $67,000. 88.23% of the stock is currently owned by institutional investors.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.